A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy ...
Dec 10, 2025
0
8
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...
Oct 28, 2025
0
39
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
14
The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University ...
Oct 20, 2025
0
97
October is Breast Cancer Awareness Month, a time to spotlight a disease that will affect hundreds of thousands of Americans this year. In the U.S., a new case of breast cancer is diagnosed about every two minutes, with more ...
Oct 6, 2025
0
20
Several factors make ovarian cancer particularly challenging to treat. This is largely because the cancer often spreads at a microscopic level within the abdomen early on, resulting in diagnosis at an advanced stage. Additionally, ...
Oct 1, 2025
0
26
Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.
Aug 11, 2025
0
20
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday.
Jun 2, 2025
0
12
The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer—particularly those with specific HER2 mutations—with manageable side ...
Apr 28, 2025
0
20
